Fluoxetine vs Sertraline: How They Compare

Fluoxetine (Prozac) and sertraline (Zoloft) are both SSRIs, and in the largest comparison of antidepressants the differences in how well they relieve depression were modest and uncertain. The practical differences are in how long they stay in the body, which approved uses and age groups each covers, how they interact with other medicines, and what is known about them in pregnancy and breastfeeding. Fluoxetine lasts much longer, which softens stopping but slows dose changes; sertraline has a half-life of about a day, so dose changes settle within about a week.

Neither is "stronger" in any reliable sense. The better choice depends on your symptoms, your other medications, your age, whether pregnancy or breastfeeding is in the picture, and how you or close relatives have responded before. That decision belongs with your prescriber, and this guide is meant to help you have that conversation.

Fluoxetine and sertraline at a glance

Do they work differently?

Both block the reuptake of serotonin, and both are standard first choices for depression and several anxiety-related conditions. The largest comparison of antidepressants, a 2018 network meta-analysis of 522 trials and 116,477 participants, found that all 21 drugs studied were more effective than placebo for adult major depression. When placebo-controlled trials were included, the differences between drugs were smaller, and the certainty of the evidence was rated moderate to very low.

The same analysis is often quoted selectively, so it helps to read both halves. In head-to-head trials only, fluoxetine was among the less efficacious drugs. On acceptability, measured as people stopping treatment for any reason, fluoxetine and sertraline were both among the better tolerated, and fluoxetine was one of only two drugs with fewer dropouts than placebo. The fair summary is that any efficacy gap between them is modest and uncertain, with wide credible intervals on most comparisons, so tolerability is often the deciding factor.

For a broader view of where SSRIs sit against SNRIs and bupropion, see how a first antidepressant is chosen, and for the other common SSRI comparison, sertraline vs escitalopram.

Half-life: the biggest practical difference

Fluoxetine and its active metabolite, norfluoxetine, are cleared slowly. The Prozac label gives an elimination half-life of 1 to 3 days after a single dose and 4 to 6 days with chronic use, and 4 to 16 days for norfluoxetine, which leads to significant accumulation and a delayed steady state. Sertraline's average terminal half-life is about 26 hours, with steady state reached after about one week of daily dosing.

What the long half-life means for you

• Dose changes take longer to show. The label warns that a change in fluoxetine dose will not be fully reflected in blood levels for several weeks, which affects how quickly a prescriber can fine-tune it.
• Side effects can linger. Because the parent drug and its metabolite are eliminated slowly, fluoxetine is still present for weeks after the last dose, including when it is stopped because of a side effect.
• Interactions outlast the last dose. Fluoxetine can still interact with other drugs after it is stopped, which is why the label requires a 5-week wait before starting an MAOI and before using thioridazine.
• Levels fall slowly. The label notes that fluoxetine and norfluoxetine levels decrease gradually when treatment ends, which may minimize discontinuation symptoms; this is also why an occasional missed dose tends to be less noticeable than with shorter-acting SSRIs.

Sertraline's shorter half-life works the other way. The label recommends a one-week interval between dose changes, so adjustments are quicker, but stopping abruptly is more likely to be felt.

Stopping and discontinuation symptoms

Both labels describe discontinuation symptoms, especially after abrupt stopping, including dizziness, irritability, sensory disturbances such as "electric shock" sensations, anxiety, headache and insomnia, and both recommend a gradual dose reduction rather than stopping suddenly.

The best direct comparison is a randomized trial in 242 people in remission on maintenance fluoxetine, sertraline or paroxetine, whose medication was secretly replaced with placebo for 5 to 8 days. People taking fluoxetine had fewer discontinuation-emergent symptoms than those on sertraline or paroxetine; symptoms were most marked with paroxetine and less so with sertraline. That trial is old and short, but its finding fits the pharmacology.

For context across all antidepressants, a 2024 meta-analysis of 79 studies estimated that 31% of people had at least one discontinuation symptom after stopping an antidepressant, compared with 17% after stopping placebo, and that severe symptoms were uncommon. Experience varies widely, which is one reason a taper is planned with the prescriber rather than improvised. If you are thinking about stopping, read what to know about discontinuing long-term medication first, and if a change of drug is the plan, how switching works.

Activation, sleep and the first few weeks

Fluoxetine has a reputation for being more "activating" than sertraline. The labels give partial support: insomnia, anxiety and nervousness appear among fluoxetine's most common adverse reactions, and in fluoxetine trials anxiety, insomnia and nervousness were among the most common reasons people stopped. Sertraline's most common reactions lean toward the gut: nausea, loose stools, indigestion and decreased appetite, along with tremor, sweating and sexual side effects.

Two cautions apply. First, the labels themselves say that side-effect rates from one drug's trials cannot be directly compared with another drug's trials. Second, individual responses vary a great deal: some people feel calmer on fluoxetine and jittery on sertraline. If restlessness, worsened anxiety or poor sleep appear early, they are worth reporting rather than enduring; this guide to SSRI activation and what to expect in the first two weeks on an SSRI explain what is common.

Both labels advise screening for bipolar disorder before starting, because any antidepressant can trigger mania or hypomania in someone at risk.

Children and teens: different approvals

This is where the two drugs differ most on paper. Fluoxetine is FDA-approved for major depression in children and adolescents from age 8 and for OCD from age 7. Sertraline is FDA-approved in young people only for OCD, ages 6 to 17; its safety and effectiveness for pediatric depression have not been established. Prescribing sertraline for a teenager's depression is therefore off-label, which is common and can be appropriate, but it is worth knowing.

The evidence base points the same way. A 2016 network meta-analysis of 34 trials in 5,260 children and adolescents with depression found that only fluoxetine was statistically significantly better than placebo, with the quality of evidence rated very low for most comparisons; the authors concluded fluoxetine is probably the best option when medication is indicated.

Both drugs carry the boxed warning that antidepressants increased suicidal thoughts and behaviors in children, adolescents and young adults in short-term studies, and both labels call for close monitoring, particularly early in treatment and after dose changes. Parents weighing medication for a teenager will find more in our parent's guide to teen depression treatment and this overview of treating adolescent depression.

Pregnancy and breastfeeding

Neither drug should be stopped abruptly because of a positive pregnancy test without talking to the prescriber. The Prozac label notes that in a study of 201 pregnant women with a history of major depression, those who stopped their antidepressant were more likely to relapse than those who continued.

Pregnancy

The fluoxetine label states that decades of epidemiologic data have not established an increased risk of major birth defects or miscarriage; some studies reported more cardiovascular malformations, but those results do not establish a causal link. It also describes the risks that apply to SSRIs as a class: persistent pulmonary hypertension of the newborn with later-pregnancy exposure, poor neonatal adaptation in some babies exposed late in the third trimester, and a less than 2-fold increase in postpartum hemorrhage risk with exposure in the month before delivery.

The label asks prescribers to consider the risk of untreated depression when stopping or changing an antidepressant during pregnancy and after delivery, which is one reason a drug that is already working is often continued rather than switched. Fluoxetine's long half-life, which keeps the drug present for weeks, is one factor clinicians weigh late in pregnancy, when the label describes newborn complications after third-trimester SSRI exposure. The full weighing is covered in psychiatric medications during pregnancy and our article on pregnancy and depression.

Breastfeeding

Here the labels differ noticeably. In a pooled analysis of 53 mother-infant pairs, exclusively breastfed infants had on average 2% of their mother's sertraline blood level, and no adverse reactions were observed. For fluoxetine, a study of 19 nursing mothers found norfluoxetine in 85% of infants' blood samples, and the label notes reports of agitation, irritability, poor feeding and poor weight gain in exposed infants. On the label data alone, sertraline has the more reassuring breastfeeding record, though a medication that has kept a mother well through pregnancy may still be the right one to continue. See psychiatric medications while breastfeeding for the questions to ask.

Drug interactions and CYP2D6

Interactions are often the deciding factor for people on several medicines. The Prozac label calls fluoxetine a potent inhibitor of the liver enzyme CYP2D6 and says it may make someone with normal CYP2D6 activity resemble a "poor metabolizer." Drugs processed by CYP2D6 include some tricyclic antidepressants, many antipsychotics and certain heart-rhythm medicines such as propafenone and flecainide, and the label advises caution when combining them.

Sertraline also inhibits CYP2D6. Its label lists substrates including atomoxetine, dextromethorphan, metoprolol, nebivolol, propafenone, flecainide and venlafaxine, and advises lowering their doses if needed and possibly raising them again if sertraline is stopped.

Both SSRIs can raise bleeding risk with NSAIDs, aspirin or blood thinners, and both can contribute to serotonin syndrome when combined with other serotonergic drugs, as their labels describe. Bring a complete list, including supplements and over-the-counter cough medicines, to every visit. If you are curious whether genetics explains past reactions, pharmacogenomic testing and its limits covers what those tests can and cannot tell you.

Heart and liver considerations

Sertraline has the stronger trial record in people with heart disease. In the SADHART trial of patients with recent heart attack or unstable angina, sertraline had no significant effect on heart pumping function, ventricular rhythm runs or QTc intervals compared with placebo, and the authors concluded it was safe and effective for recurrent depression in that group. Both labels still list QT prolongation as a precaution.

With liver disease, both labels call for adjustments: fluoxetine at a lower or less frequent dose, and sertraline at half the usual dose in mild impairment and not recommended in moderate or severe impairment. Your prescriber may want recent labs before deciding.

How the choice usually plays out

These are tendencies, not rules. Prior response is often the strongest predictor: if a drug worked well for you, or for a parent or sibling, that history counts.

Questions to ask your prescriber

• Given my other medications, which of these has fewer interaction concerns for me?
• How long should I give this before we judge whether it is working, and what would make us change the dose?
• Which side effects should I report right away, and which tend to fade?
• If I want to stop someday, what would a taper look like with this drug?
• If I might become pregnant or plan to breastfeed, does that change your recommendation?
• What is the plan if this one does not help enough? (See what a psychiatrist considers next.)

Never start, stop or change the dose of either medication on your own; side effects, interactions and discontinuation symptoms are all easier to manage with a plan. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

How Dr. Lewis's practice approaches this choice

The practice's psychiatrists and psychiatric nurse practitioners provide psychiatric evaluation and medication management alongside psychotherapy, coaching, lab testing, and nutrition and lifestyle psychiatry, so a medication decision can sit inside a wider plan. You can read about medication management at the practice, and new patients start with a free discovery call or the Patient Interest Form. More comparisons like this one are collected in the Choosing Psychiatric Care guide.

Frequently asked questions

Can I switch from sertraline to fluoxetine, or the other way around?

Yes, prescribers make this switch regularly, but the method depends on your doses, how long you have taken the current drug and your other medications. Fluoxetine's long half-life means it lingers after it is stopped, which affects timing. Plan it with your prescriber rather than swapping on your own; see switching antidepressants.

Is one of them better for anxiety?

Sertraline is FDA-approved for panic disorder, PTSD and social anxiety disorder, and fluoxetine for panic disorder and OCD. Both are used for anxiety more broadly. Approval differences reflect which trials the manufacturer ran, not proof that one is more effective in a given person.

Which causes more weight gain?

Neither label lists weight gain among its most common adverse reactions in adults. Weight changes over longer treatment vary by person. If weight is a concern, raise it at the start so it can be tracked; this article on antidepressant weight changes covers practical steps.

Do fluoxetine and sertraline cause sexual side effects equally?

Both commonly do. A meta-analysis found that both raised rates of treatment-emergent sexual dysfunction compared with placebo, as did most SSRIs and SNRIs. If it happens, there are options, from timing and dose changes to other medications, so mention it rather than stopping.

Is there a weekly version of fluoxetine?

A once-weekly 90 mg delayed-release fluoxetine capsule was studied for maintenance after people responded to daily fluoxetine, and the Prozac label describes that trial. Whether a weekly form is suitable or available for you is a question for your prescriber and pharmacist.

Are the generic versions as good as Prozac and Zoloft?

Generic fluoxetine and sertraline contain the same active ingredients as Prozac and Zoloft and are widely used. Occasional differences in how people feel after a manufacturer change are worth reporting. See generic vs brand psychiatric medications.

Sources

1. PROZAC (fluoxetine capsules) prescribing information. Eli Lilly and Company via DailyMed (U.S. National Library of Medicine), 2026. dailymed.nlm.nih.gov
2. ZOLOFT (sertraline hydrochloride) tablets and oral solution prescribing information. Viatris Specialty LLC via DailyMed (U.S. National Library of Medicine), 2025. dailymed.nlm.nih.gov
3. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet (Cipriani et al.), 2018. pubmed.ncbi.nlm.nih.gov
4. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry (Rosenbaum et al.), 1998. pubmed.ncbi.nlm.nih.gov
5. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. The Lancet (Cipriani et al.), 2016. pubmed.ncbi.nlm.nih.gov
6. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry (Henssler et al.), 2024. pubmed.ncbi.nlm.nih.gov
7. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (Glassman et al., SADHART), 2002. pubmed.ncbi.nlm.nih.gov
8. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology (Serretti and Chiesa), 2009. pubmed.ncbi.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.